nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—Folic Acid Metabolism Inhibitors—Methotrexate—bone cancer	0.287	1	CiPCiCtD
Pemetrexed—Methotrexate—bone cancer	0.189	1	CrCtD
Pemetrexed—lung cancer—bone cancer	0.139	1	CtDrD
Pemetrexed—DHFR—bone cancer	0.12	1	CbGaD
Pemetrexed—ATIC—Methotrexate—bone cancer	0.0392	0.377	CbGbCtD
Pemetrexed—SLC46A1—Methotrexate—bone cancer	0.0312	0.299	CbGbCtD
Pemetrexed—Raltitrexed—Methotrexate—bone cancer	0.0251	0.2	CrCrCtD
Pemetrexed—Folic Acid—Methotrexate—bone cancer	0.0251	0.2	CrCrCtD
Pemetrexed—Pralatrexate—Methotrexate—bone cancer	0.0251	0.2	CrCrCtD
Pemetrexed—Leucovorin—Methotrexate—bone cancer	0.0251	0.2	CrCrCtD
Pemetrexed—Tetrahydrofolic acid—Methotrexate—bone cancer	0.0251	0.2	CrCrCtD
Pemetrexed—DHFR—Methotrexate—bone cancer	0.0199	0.191	CbGbCtD
Pemetrexed—TYMS—Methotrexate—bone cancer	0.0139	0.133	CbGbCtD
Pemetrexed—ATIC—pes—bone cancer	0.00201	0.235	CbGeAlD
Pemetrexed—GART—Folate Metabolism—FOLR1—bone cancer	0.00133	0.0969	CbGpPWpGaD
Pemetrexed—ATIC—leg—bone cancer	0.00102	0.12	CbGeAlD
Pemetrexed—ATIC—forelimb—bone cancer	0.00101	0.119	CbGeAlD
Pemetrexed—SLC46A1—Metabolism of folate and pterines—DHFR—bone cancer	0.000968	0.0707	CbGpPWpGaD
Pemetrexed—ATIC—hindlimb—bone cancer	0.000913	0.107	CbGeAlD
Pemetrexed—GART—Nucleotide metabolism—NT5C3A—bone cancer	0.000784	0.0573	CbGpPWpGaD
Pemetrexed—ATIC—appendage—bone cancer	0.000783	0.0918	CbGeAlD
Pemetrexed—DCK—Pyrimidine metabolism—NT5C3A—bone cancer	0.000725	0.053	CbGpPWpGaD
Pemetrexed—GART—One Carbon Metabolism—DHFR—bone cancer	0.000723	0.0528	CbGpPWpGaD
Pemetrexed—SLC46A1—Folate Metabolism—FOLR1—bone cancer	0.000716	0.0523	CbGpPWpGaD
Pemetrexed—ATIC—Nucleotide metabolism—NT5C3A—bone cancer	0.000543	0.0397	CbGpPWpGaD
Pemetrexed—TYMS—Pyrimidine metabolism—NT5C3A—bone cancer	0.000509	0.0372	CbGpPWpGaD
Pemetrexed—ATIC—One Carbon Metabolism—DHFR—bone cancer	0.000501	0.0366	CbGpPWpGaD
Pemetrexed—Methotrexate—FOLR1—bone cancer	0.000425	0.428	CrCbGaD
Pemetrexed—Pralatrexate—DHFR—bone cancer	0.000395	0.397	CrCbGaD
Pemetrexed—DHFR—Folate Metabolism—FOLR1—bone cancer	0.000384	0.0281	CbGpPWpGaD
Pemetrexed—GART—Folate Metabolism—DHFR—bone cancer	0.000364	0.0266	CbGpPWpGaD
Pemetrexed—DCK—Nucleotide metabolism—NT5C3A—bone cancer	0.000282	0.0206	CbGpPWpGaD
Pemetrexed—TYMS—G1/S-Specific Transcription—DHFR—bone cancer	0.000272	0.0199	CbGpPWpGaD
Pemetrexed—SLC29A1—Fluoropyrimidine Activity—DHFR—bone cancer	0.000271	0.0198	CbGpPWpGaD
Pemetrexed—GART—tendon—bone cancer	0.000226	0.0265	CbGeAlD
Pemetrexed—ATIC—connective tissue—bone cancer	0.000223	0.0262	CbGeAlD
Pemetrexed—GART—bone marrow—bone cancer	0.000219	0.0257	CbGeAlD
Pemetrexed—GART—spinal cord—bone cancer	0.000218	0.0256	CbGeAlD
Pemetrexed—TYMS—Nucleotide metabolism—NT5C3A—bone cancer	0.000198	0.0145	CbGpPWpGaD
Pemetrexed—SLC46A1—Folate Metabolism—DHFR—bone cancer	0.000197	0.0144	CbGpPWpGaD
Pemetrexed—SLC46A1—tendon—bone cancer	0.000184	0.0215	CbGeAlD
Pemetrexed—TYMS—One Carbon Metabolism—DHFR—bone cancer	0.000183	0.0133	CbGpPWpGaD
Pemetrexed—DCK—Doxorubicin—Epirubicin—bone cancer	0.000179	0.519	CbGdCrCtD
Pemetrexed—SLC46A1—spinal cord—bone cancer	0.000177	0.0208	CbGeAlD
Pemetrexed—Methotrexate—DHFR—bone cancer	0.000174	0.175	CrCbGaD
Pemetrexed—DCK—Epirubicin—Doxorubicin—bone cancer	0.000166	0.481	CbGdCrCtD
Pemetrexed—TYMS—Trans-sulfuration and one carbon metabolism—DHFR—bone cancer	0.000164	0.012	CbGpPWpGaD
Pemetrexed—TYMS—E2F mediated regulation of DNA replication—DHFR—bone cancer	0.00016	0.0117	CbGpPWpGaD
Pemetrexed—TYMS—Fluoropyrimidine Activity—DHFR—bone cancer	0.00016	0.0117	CbGpPWpGaD
Pemetrexed—SLC46A1—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000158	0.0115	CbGpPWpGaD
Pemetrexed—TYMS—connective tissue—bone cancer	0.000152	0.0178	CbGeAlD
Pemetrexed—DHFR—connective tissue—bone cancer	0.00015	0.0176	CbGeAlD
Pemetrexed—ATIC—spinal cord—bone cancer	0.000148	0.0174	CbGeAlD
Pemetrexed—SLC29A1—connective tissue—bone cancer	0.000136	0.0159	CbGeAlD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.000105	0.00768	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000104	0.00761	CbGpPWpGaD
Pemetrexed—TYMS—tendon—bone cancer	0.000104	0.0122	CbGeAlD
Pemetrexed—DHFR—tendon—bone cancer	0.000103	0.0121	CbGeAlD
Pemetrexed—TYMS—bone marrow—bone cancer	0.000101	0.0118	CbGeAlD
Pemetrexed—DHFR—bone marrow—bone cancer	9.99e-05	0.0117	CbGeAlD
Pemetrexed—DHFR—spinal cord—bone cancer	9.95e-05	0.0117	CbGeAlD
Pemetrexed—SLC29A1—tendon—bone cancer	9.34e-05	0.011	CbGeAlD
Pemetrexed—SLC29A1—bone marrow—bone cancer	9.05e-05	0.0106	CbGeAlD
Pemetrexed—DCK—tendon—bone cancer	8.93e-05	0.0105	CbGeAlD
Pemetrexed—DCK—bone marrow—bone cancer	8.65e-05	0.0101	CbGeAlD
Pemetrexed—DCK—spinal cord—bone cancer	8.61e-05	0.0101	CbGeAlD
Pemetrexed—GART—Metabolism—NDUFA12—bone cancer	8.59e-05	0.00628	CbGpPWpGaD
Pemetrexed—TYMS—E2F transcription factor network—DHFR—bone cancer	8.49e-05	0.0062	CbGpPWpGaD
Pemetrexed—DHFR—E2F mediated regulation of DNA replication—RB1—bone cancer	8.38e-05	0.00613	CbGpPWpGaD
Pemetrexed—GART—Folate Metabolism—TP53—bone cancer	8.14e-05	0.00594	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	7.38e-05	0.00539	CbGpPWpGaD
Pemetrexed—TYMS—E2F mediated regulation of DNA replication—RB1—bone cancer	7.32e-05	0.00534	CbGpPWpGaD
Pemetrexed—GART—Metabolism—NT5C3A—bone cancer	7.12e-05	0.0052	CbGpPWpGaD
Pemetrexed—TYMS—G1/S Transition—DHFR—bone cancer	6.16e-05	0.0045	CbGpPWpGaD
Pemetrexed—SLC29A1—Fluoropyrimidine Activity—TP53—bone cancer	6.07e-05	0.00443	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—NDUFA12—bone cancer	5.96e-05	0.00435	CbGpPWpGaD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	5.94e-05	0.00434	CbGpPWpGaD
Pemetrexed—SLC46A1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	5.92e-05	0.00432	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	5.53e-05	0.00404	CbGpPWpGaD
Pemetrexed—DHFR—E2F transcription factor network—PLAU—bone cancer	5.41e-05	0.00395	CbGpPWpGaD
Pemetrexed—Hepatobiliary disease—Cisplatin—bone cancer	5.23e-05	0.0045	CcSEcCtD
Pemetrexed—Rectal haemorrhage—Doxorubicin—bone cancer	5.2e-05	0.00448	CcSEcCtD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—DHFR—bone cancer	5.19e-05	0.00379	CbGpPWpGaD
Pemetrexed—Skin exfoliation—Methotrexate—bone cancer	5.18e-05	0.00446	CcSEcCtD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.12e-05	0.00374	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—ZW10—bone cancer	5.12e-05	0.00374	CbGpPWpGaD
Pemetrexed—Lacrimation increased—Doxorubicin—bone cancer	5.1e-05	0.00439	CcSEcCtD
Pemetrexed—Ventricular tachycardia—Epirubicin—bone cancer	5.08e-05	0.00437	CcSEcCtD
Pemetrexed—Pulmonary embolism—Epirubicin—bone cancer	5.08e-05	0.00437	CcSEcCtD
Pemetrexed—ATIC—Metabolism—NT5C3A—bone cancer	4.94e-05	0.00361	CbGpPWpGaD
Pemetrexed—Creatinine increased—Doxorubicin—bone cancer	4.93e-05	0.00425	CcSEcCtD
Pemetrexed—Urinary tract disorder—Cisplatin—bone cancer	4.9e-05	0.00422	CcSEcCtD
Pemetrexed—Colitis—Epirubicin—bone cancer	4.87e-05	0.0042	CcSEcCtD
Pemetrexed—Urethral disorder—Cisplatin—bone cancer	4.87e-05	0.00419	CcSEcCtD
Pemetrexed—Skin exfoliation—Epirubicin—bone cancer	4.85e-05	0.00417	CcSEcCtD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—RB1—bone cancer	4.8e-05	0.00351	CbGpPWpGaD
Pemetrexed—Neuropathy—Epirubicin—bone cancer	4.77e-05	0.0041	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	4.72e-05	0.00345	CbGpPWpGaD
Pemetrexed—TYMS—E2F transcription factor network—PLAU—bone cancer	4.72e-05	0.00345	CbGpPWpGaD
Pemetrexed—Sepsis—Methotrexate—bone cancer	4.71e-05	0.00405	CcSEcCtD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.71e-05	0.00344	CbGpPWpGaD
Pemetrexed—Ventricular tachycardia—Doxorubicin—bone cancer	4.7e-05	0.00405	CcSEcCtD
Pemetrexed—Pulmonary embolism—Doxorubicin—bone cancer	4.7e-05	0.00405	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—NDUFA12—bone cancer	4.64e-05	0.00339	CbGpPWpGaD
Pemetrexed—Eye disorder—Cisplatin—bone cancer	4.64e-05	0.004	CcSEcCtD
Pemetrexed—Oesophagitis—Epirubicin—bone cancer	4.64e-05	0.004	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—ZW10—bone cancer	4.58e-05	0.00334	CbGpPWpGaD
Pemetrexed—Colitis—Doxorubicin—bone cancer	4.51e-05	0.00388	CcSEcCtD
Pemetrexed—Skin exfoliation—Doxorubicin—bone cancer	4.48e-05	0.00386	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—ZW10—bone cancer	4.47e-05	0.00326	CbGpPWpGaD
Pemetrexed—DHFR—E2F transcription factor network—RB1—bone cancer	4.44e-05	0.00325	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	4.44e-05	0.00324	CbGpPWpGaD
Pemetrexed—Arrhythmia—Cisplatin—bone cancer	4.44e-05	0.00382	CcSEcCtD
Pemetrexed—Neuropathy—Doxorubicin—bone cancer	4.41e-05	0.0038	CcSEcCtD
Pemetrexed—Sepsis—Epirubicin—bone cancer	4.41e-05	0.00379	CcSEcCtD
Pemetrexed—SLC46A1—Folate Metabolism—TP53—bone cancer	4.39e-05	0.00321	CbGpPWpGaD
Pemetrexed—Alopecia—Cisplatin—bone cancer	4.39e-05	0.00378	CcSEcCtD
Pemetrexed—Malnutrition—Cisplatin—bone cancer	4.32e-05	0.00372	CcSEcCtD
Pemetrexed—Erythema—Cisplatin—bone cancer	4.32e-05	0.00372	CcSEcCtD
Pemetrexed—Oesophagitis—Doxorubicin—bone cancer	4.29e-05	0.0037	CcSEcCtD
Pemetrexed—Renal failure acute—Methotrexate—bone cancer	4.27e-05	0.00367	CcSEcCtD
Pemetrexed—DHFR—Fluoropyrimidine Activity—TP53—bone cancer	4.1e-05	0.003	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	4.1e-05	0.00299	CbGpPWpGaD
Pemetrexed—Sepsis—Doxorubicin—bone cancer	4.08e-05	0.00351	CcSEcCtD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.06e-05	0.00297	CbGpPWpGaD
Pemetrexed—Cerebrovascular accident—Methotrexate—bone cancer	4.02e-05	0.00346	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	4.02e-05	0.00294	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—ZW10—bone cancer	4e-05	0.00292	CbGpPWpGaD
Pemetrexed—Anaemia—Cisplatin—bone cancer	3.99e-05	0.00344	CcSEcCtD
Pemetrexed—Renal failure acute—Epirubicin—bone cancer	3.99e-05	0.00344	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—TUBB4B—bone cancer	3.88e-05	0.00284	CbGpPWpGaD
Pemetrexed—TYMS—E2F transcription factor network—RB1—bone cancer	3.88e-05	0.00283	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	3.87e-05	0.00283	CbGpPWpGaD
Pemetrexed—Leukopenia—Cisplatin—bone cancer	3.87e-05	0.00333	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—RB1—bone cancer	3.86e-05	0.00282	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—NT5C3A—bone cancer	3.85e-05	0.00281	CbGpPWpGaD
Pemetrexed—Cerebrovascular accident—Epirubicin—bone cancer	3.76e-05	0.00324	CcSEcCtD
Pemetrexed—Mood swings—Methotrexate—bone cancer	3.73e-05	0.00321	CcSEcCtD
Pemetrexed—Renal failure acute—Doxorubicin—bone cancer	3.69e-05	0.00318	CcSEcCtD
Pemetrexed—Myalgia—Cisplatin—bone cancer	3.68e-05	0.00317	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	3.66e-05	0.00267	CbGpPWpGaD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	3.65e-05	0.00315	CcSEcCtD
Pemetrexed—TYMS—Fluoropyrimidine Activity—TP53—bone cancer	3.58e-05	0.00261	CbGpPWpGaD
Pemetrexed—Toxic epidermal necrolysis—Methotrexate—bone cancer	3.55e-05	0.00305	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—GNA11—bone cancer	3.53e-05	0.00258	CbGpPWpGaD
Pemetrexed—Anaphylactic shock—Cisplatin—bone cancer	3.53e-05	0.00304	CcSEcCtD
Pemetrexed—Oedema—Cisplatin—bone cancer	3.53e-05	0.00304	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—RFC1—bone cancer	3.52e-05	0.00257	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—EZH2—bone cancer	3.51e-05	0.00257	CbGpPWpGaD
Pemetrexed—Infection—Cisplatin—bone cancer	3.5e-05	0.00302	CcSEcCtD
Pemetrexed—Mood swings—Epirubicin—bone cancer	3.49e-05	0.00301	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Doxorubicin—bone cancer	3.48e-05	0.003	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—TUBB4B—bone cancer	3.47e-05	0.00254	CbGpPWpGaD
Pemetrexed—Nervous system disorder—Cisplatin—bone cancer	3.46e-05	0.00298	CcSEcCtD
Pemetrexed—Thrombocytopenia—Cisplatin—bone cancer	3.45e-05	0.00297	CcSEcCtD
Pemetrexed—Blood creatinine increased—Epirubicin—bone cancer	3.45e-05	0.00297	CcSEcCtD
Pemetrexed—Dehydration—Epirubicin—bone cancer	3.43e-05	0.00295	CcSEcCtD
Pemetrexed—Skin disorder—Cisplatin—bone cancer	3.43e-05	0.00295	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—TUBB4B—bone cancer	3.39e-05	0.00247	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—RB1—bone cancer	3.37e-05	0.00246	CbGpPWpGaD
Pemetrexed—Anorexia—Cisplatin—bone cancer	3.36e-05	0.0029	CcSEcCtD
Pemetrexed—Pancreatitis—Methotrexate—bone cancer	3.34e-05	0.00287	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	3.33e-05	0.00243	CbGpPWpGaD
Pemetrexed—Aspartate aminotransferase increased—Epirubicin—bone cancer	3.32e-05	0.00286	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Epirubicin—bone cancer	3.32e-05	0.00286	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	3.29e-05	0.0024	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	3.29e-05	0.0024	CbGpPWpGaD
Pemetrexed—Alanine aminotransferase increased—Epirubicin—bone cancer	3.25e-05	0.0028	CcSEcCtD
Pemetrexed—Pancytopenia—Methotrexate—bone cancer	3.23e-05	0.00278	CcSEcCtD
Pemetrexed—Mood swings—Doxorubicin—bone cancer	3.23e-05	0.00278	CcSEcCtD
Pemetrexed—DHFR—G1/S Transition—RB1—bone cancer	3.22e-05	0.00235	CbGpPWpGaD
Pemetrexed—Musculoskeletal discomfort—Cisplatin—bone cancer	3.21e-05	0.00277	CcSEcCtD
Pemetrexed—Blood creatinine increased—Doxorubicin—bone cancer	3.19e-05	0.00275	CcSEcCtD
Pemetrexed—Dysphagia—Epirubicin—bone cancer	3.19e-05	0.00274	CcSEcCtD
Pemetrexed—Neutropenia—Methotrexate—bone cancer	3.18e-05	0.00274	CcSEcCtD
Pemetrexed—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	3.17e-05	0.00232	CbGpPWpGaD
Pemetrexed—Dehydration—Doxorubicin—bone cancer	3.17e-05	0.00273	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—RFC1—bone cancer	3.15e-05	0.0023	CbGpPWpGaD
Pemetrexed—Dyspnoea—Cisplatin—bone cancer	3.14e-05	0.00271	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CDK4—bone cancer	3.12e-05	0.00228	CbGpPWpGaD
Pemetrexed—Pancreatitis—Epirubicin—bone cancer	3.12e-05	0.00269	CcSEcCtD
Pemetrexed—GART—Metabolism—ENO2—bone cancer	3.12e-05	0.00228	CbGpPWpGaD
Pemetrexed—Angina pectoris—Epirubicin—bone cancer	3.1e-05	0.00267	CcSEcCtD
Pemetrexed—DCK—Metabolism—NDUFA12—bone cancer	3.1e-05	0.00226	CbGpPWpGaD
Pemetrexed—Toxic epidermal necrolysis—Doxorubicin—bone cancer	3.07e-05	0.00264	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Doxorubicin—bone cancer	3.07e-05	0.00264	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—RFC1—bone cancer	3.07e-05	0.00224	CbGpPWpGaD
Pemetrexed—Decreased appetite—Cisplatin—bone cancer	3.07e-05	0.00264	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Cisplatin—bone cancer	3.05e-05	0.00262	CcSEcCtD
Pemetrexed—Infestation NOS—Methotrexate—bone cancer	3.03e-05	0.00261	CcSEcCtD
Pemetrexed—Infestation—Methotrexate—bone cancer	3.03e-05	0.00261	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—TUBB4B—bone cancer	3.03e-05	0.00221	CbGpPWpGaD
Pemetrexed—Pancytopenia—Epirubicin—bone cancer	3.02e-05	0.0026	CcSEcCtD
Pemetrexed—Pain—Cisplatin—bone cancer	3.02e-05	0.0026	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Methotrexate—bone cancer	3.01e-05	0.00259	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Doxorubicin—bone cancer	3.01e-05	0.00259	CcSEcCtD
Pemetrexed—Renal failure—Methotrexate—bone cancer	2.98e-05	0.00257	CcSEcCtD
Pemetrexed—Neutropenia—Epirubicin—bone cancer	2.98e-05	0.00256	CcSEcCtD
Pemetrexed—Stomatitis—Methotrexate—bone cancer	2.96e-05	0.00255	CcSEcCtD
Pemetrexed—Conjunctivitis—Methotrexate—bone cancer	2.95e-05	0.00254	CcSEcCtD
Pemetrexed—Dysphagia—Doxorubicin—bone cancer	2.95e-05	0.00254	CcSEcCtD
Pemetrexed—GART—Metabolism—DHFR—bone cancer	2.89e-05	0.00211	CbGpPWpGaD
Pemetrexed—Pancreatitis—Doxorubicin—bone cancer	2.89e-05	0.00249	CcSEcCtD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	2.87e-05	0.0021	CbGpPWpGaD
Pemetrexed—Angina pectoris—Doxorubicin—bone cancer	2.87e-05	0.00247	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Methotrexate—bone cancer	2.87e-05	0.00247	CcSEcCtD
Pemetrexed—Infestation—Epirubicin—bone cancer	2.84e-05	0.00245	CcSEcCtD
Pemetrexed—Infestation NOS—Epirubicin—bone cancer	2.84e-05	0.00245	CcSEcCtD
Pemetrexed—Agranulocytosis—Methotrexate—bone cancer	2.83e-05	0.00244	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Epirubicin—bone cancer	2.82e-05	0.00242	CcSEcCtD
Pemetrexed—TYMS—G1/S Transition—RB1—bone cancer	2.81e-05	0.00205	CbGpPWpGaD
Pemetrexed—Pancytopenia—Doxorubicin—bone cancer	2.8e-05	0.00241	CcSEcCtD
Pemetrexed—Renal failure—Epirubicin—bone cancer	2.79e-05	0.0024	CcSEcCtD
Pemetrexed—Body temperature increased—Cisplatin—bone cancer	2.79e-05	0.0024	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	2.78e-05	0.00203	CbGpPWpGaD
Pemetrexed—Neuropathy peripheral—Epirubicin—bone cancer	2.78e-05	0.0024	CcSEcCtD
Pemetrexed—Stomatitis—Epirubicin—bone cancer	2.77e-05	0.00238	CcSEcCtD
Pemetrexed—Conjunctivitis—Epirubicin—bone cancer	2.76e-05	0.00238	CcSEcCtD
Pemetrexed—Neutropenia—Doxorubicin—bone cancer	2.76e-05	0.00237	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—RFC1—bone cancer	2.75e-05	0.00201	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDK4—bone cancer	2.73e-05	0.00199	CbGpPWpGaD
Pemetrexed—Hepatitis—Methotrexate—bone cancer	2.72e-05	0.00235	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—RB1—bone cancer	2.72e-05	0.00198	CbGpPWpGaD
Pemetrexed—GART—Metabolism—GNA11—bone cancer	2.7e-05	0.00198	CbGpPWpGaD
Pemetrexed—Pharyngitis—Methotrexate—bone cancer	2.7e-05	0.00233	CcSEcCtD
Pemetrexed—Urinary tract disorder—Methotrexate—bone cancer	2.69e-05	0.00232	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Epirubicin—bone cancer	2.69e-05	0.00231	CcSEcCtD
Pemetrexed—Urethral disorder—Methotrexate—bone cancer	2.67e-05	0.0023	CcSEcCtD
Pemetrexed—Agranulocytosis—Epirubicin—bone cancer	2.65e-05	0.00228	CcSEcCtD
Pemetrexed—Infestation—Doxorubicin—bone cancer	2.63e-05	0.00226	CcSEcCtD
Pemetrexed—Infestation NOS—Doxorubicin—bone cancer	2.63e-05	0.00226	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Doxorubicin—bone cancer	2.61e-05	0.00224	CcSEcCtD
Pemetrexed—Hypersensitivity—Cisplatin—bone cancer	2.6e-05	0.00224	CcSEcCtD
Pemetrexed—Renal failure—Doxorubicin—bone cancer	2.58e-05	0.00222	CcSEcCtD
Pemetrexed—Erythema multiforme—Methotrexate—bone cancer	2.58e-05	0.00222	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Doxorubicin—bone cancer	2.58e-05	0.00222	CcSEcCtD
Pemetrexed—DCK—Metabolism—NT5C3A—bone cancer	2.57e-05	0.00187	CbGpPWpGaD
Pemetrexed—Stomatitis—Doxorubicin—bone cancer	2.56e-05	0.00221	CcSEcCtD
Pemetrexed—Conjunctivitis—Doxorubicin—bone cancer	2.55e-05	0.0022	CcSEcCtD
Pemetrexed—Hepatitis—Epirubicin—bone cancer	2.55e-05	0.0022	CcSEcCtD
Pemetrexed—Eye disorder—Methotrexate—bone cancer	2.55e-05	0.00219	CcSEcCtD
Pemetrexed—Asthenia—Cisplatin—bone cancer	2.53e-05	0.00218	CcSEcCtD
Pemetrexed—Pharyngitis—Epirubicin—bone cancer	2.53e-05	0.00218	CcSEcCtD
Pemetrexed—Urinary tract disorder—Epirubicin—bone cancer	2.52e-05	0.00217	CcSEcCtD
Pemetrexed—Urethral disorder—Epirubicin—bone cancer	2.5e-05	0.00215	CcSEcCtD
Pemetrexed—DHFR—Metabolism—NDUFA12—bone cancer	2.49e-05	0.00182	CbGpPWpGaD
Pemetrexed—Hepatobiliary disease—Doxorubicin—bone cancer	2.49e-05	0.00214	CcSEcCtD
Pemetrexed—Agranulocytosis—Doxorubicin—bone cancer	2.45e-05	0.00211	CcSEcCtD
Pemetrexed—GART—Metabolism—CYP3A4—bone cancer	2.45e-05	0.00179	CbGpPWpGaD
Pemetrexed—Diarrhoea—Cisplatin—bone cancer	2.41e-05	0.00208	CcSEcCtD
Pemetrexed—Erythema multiforme—Epirubicin—bone cancer	2.41e-05	0.00208	CcSEcCtD
Pemetrexed—Alopecia—Methotrexate—bone cancer	2.41e-05	0.00207	CcSEcCtD
Pemetrexed—Eye disorder—Epirubicin—bone cancer	2.38e-05	0.00205	CcSEcCtD
Pemetrexed—Malnutrition—Methotrexate—bone cancer	2.37e-05	0.00204	CcSEcCtD
Pemetrexed—Erythema—Methotrexate—bone cancer	2.37e-05	0.00204	CcSEcCtD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—RB1—bone cancer	2.37e-05	0.00173	CbGpPWpGaD
Pemetrexed—Hepatitis—Doxorubicin—bone cancer	2.36e-05	0.00203	CcSEcCtD
Pemetrexed—DHFR—Folate Metabolism—TP53—bone cancer	2.36e-05	0.00172	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—TP53—bone cancer	2.35e-05	0.00172	CbGpPWpGaD
Pemetrexed—Pharyngitis—Doxorubicin—bone cancer	2.34e-05	0.00202	CcSEcCtD
Pemetrexed—Urinary tract disorder—Doxorubicin—bone cancer	2.33e-05	0.00201	CcSEcCtD
Pemetrexed—Dysgeusia—Methotrexate—bone cancer	2.32e-05	0.002	CcSEcCtD
Pemetrexed—Urethral disorder—Doxorubicin—bone cancer	2.31e-05	0.00199	CcSEcCtD
Pemetrexed—Arrhythmia—Epirubicin—bone cancer	2.28e-05	0.00196	CcSEcCtD
Pemetrexed—Alopecia—Epirubicin—bone cancer	2.25e-05	0.00194	CcSEcCtD
Pemetrexed—Vomiting—Cisplatin—bone cancer	2.24e-05	0.00193	CcSEcCtD
Pemetrexed—Erythema multiforme—Doxorubicin—bone cancer	2.23e-05	0.00192	CcSEcCtD
Pemetrexed—Rash—Cisplatin—bone cancer	2.22e-05	0.00192	CcSEcCtD
Pemetrexed—Dermatitis—Cisplatin—bone cancer	2.22e-05	0.00191	CcSEcCtD
Pemetrexed—Erythema—Epirubicin—bone cancer	2.22e-05	0.00191	CcSEcCtD
Pemetrexed—Malnutrition—Epirubicin—bone cancer	2.22e-05	0.00191	CcSEcCtD
Pemetrexed—Eye disorder—Doxorubicin—bone cancer	2.2e-05	0.0019	CcSEcCtD
Pemetrexed—Anaemia—Methotrexate—bone cancer	2.19e-05	0.00189	CcSEcCtD
Pemetrexed—Dysgeusia—Epirubicin—bone cancer	2.17e-05	0.00187	CcSEcCtD
Pemetrexed—TYMS—Metabolism—NDUFA12—bone cancer	2.17e-05	0.00159	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—ENO2—bone cancer	2.16e-05	0.00158	CbGpPWpGaD
Pemetrexed—Leukopenia—Methotrexate—bone cancer	2.12e-05	0.00183	CcSEcCtD
Pemetrexed—Arrhythmia—Doxorubicin—bone cancer	2.11e-05	0.00181	CcSEcCtD
Pemetrexed—GART—Metabolism—GSTP1—bone cancer	2.1e-05	0.00153	CbGpPWpGaD
Pemetrexed—Nausea—Cisplatin—bone cancer	2.1e-05	0.0018	CcSEcCtD
Pemetrexed—Alopecia—Doxorubicin—bone cancer	2.08e-05	0.0018	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	2.07e-05	0.00151	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NT5C3A—bone cancer	2.06e-05	0.00151	CbGpPWpGaD
Pemetrexed—Malnutrition—Doxorubicin—bone cancer	2.05e-05	0.00177	CcSEcCtD
Pemetrexed—Erythema—Doxorubicin—bone cancer	2.05e-05	0.00177	CcSEcCtD
Pemetrexed—Anaemia—Epirubicin—bone cancer	2.05e-05	0.00177	CcSEcCtD
Pemetrexed—Chest pain—Methotrexate—bone cancer	2.02e-05	0.00174	CcSEcCtD
Pemetrexed—Arthralgia—Methotrexate—bone cancer	2.02e-05	0.00174	CcSEcCtD
Pemetrexed—Myalgia—Methotrexate—bone cancer	2.02e-05	0.00174	CcSEcCtD
Pemetrexed—SLC46A1—Disease—ENO2—bone cancer	2.01e-05	0.00147	CbGpPWpGaD
Pemetrexed—Dysgeusia—Doxorubicin—bone cancer	2.01e-05	0.00173	CcSEcCtD
Pemetrexed—ATIC—Metabolism—DHFR—bone cancer	2.01e-05	0.00147	CbGpPWpGaD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	2.01e-05	0.00173	CcSEcCtD
Pemetrexed—Syncope—Epirubicin—bone cancer	1.99e-05	0.00171	CcSEcCtD
Pemetrexed—Leukopenia—Epirubicin—bone cancer	1.99e-05	0.00171	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—CDK4—bone cancer	1.98e-05	0.00145	CbGpPWpGaD
Pemetrexed—Loss of consciousness—Epirubicin—bone cancer	1.95e-05	0.00168	CcSEcCtD
Pemetrexed—Anaphylactic shock—Methotrexate—bone cancer	1.94e-05	0.00167	CcSEcCtD
Pemetrexed—Infection—Methotrexate—bone cancer	1.92e-05	0.00166	CcSEcCtD
Pemetrexed—Hypertension—Epirubicin—bone cancer	1.92e-05	0.00165	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—DHFR—bone cancer	1.9e-05	0.00139	CbGpPWpGaD
Pemetrexed—Nervous system disorder—Methotrexate—bone cancer	1.9e-05	0.00163	CcSEcCtD
Pemetrexed—Anaemia—Doxorubicin—bone cancer	1.9e-05	0.00163	CcSEcCtD
Pemetrexed—Thrombocytopenia—Methotrexate—bone cancer	1.9e-05	0.00163	CcSEcCtD
Pemetrexed—Arthralgia—Epirubicin—bone cancer	1.89e-05	0.00163	CcSEcCtD
Pemetrexed—Myalgia—Epirubicin—bone cancer	1.89e-05	0.00163	CcSEcCtD
Pemetrexed—Chest pain—Epirubicin—bone cancer	1.89e-05	0.00163	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—TP53—bone cancer	1.89e-05	0.00138	CbGpPWpGaD
Pemetrexed—Skin disorder—Methotrexate—bone cancer	1.88e-05	0.00162	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	1.88e-05	0.00162	CcSEcCtD
Pemetrexed—ATIC—Metabolism—GNA11—bone cancer	1.87e-05	0.00137	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—DHFR—bone cancer	1.87e-05	0.00136	CbGpPWpGaD
Pemetrexed—Anorexia—Methotrexate—bone cancer	1.84e-05	0.00159	CcSEcCtD
Pemetrexed—Syncope—Doxorubicin—bone cancer	1.84e-05	0.00159	CcSEcCtD
Pemetrexed—Leukopenia—Doxorubicin—bone cancer	1.84e-05	0.00158	CcSEcCtD
Pemetrexed—Anaphylactic shock—Epirubicin—bone cancer	1.81e-05	0.00156	CcSEcCtD
Pemetrexed—Oedema—Epirubicin—bone cancer	1.81e-05	0.00156	CcSEcCtD
Pemetrexed—Loss of consciousness—Doxorubicin—bone cancer	1.8e-05	0.00155	CcSEcCtD
Pemetrexed—Infection—Epirubicin—bone cancer	1.8e-05	0.00155	CcSEcCtD
Pemetrexed—TYMS—Metabolism—NT5C3A—bone cancer	1.8e-05	0.00131	CbGpPWpGaD
Pemetrexed—Shock—Epirubicin—bone cancer	1.78e-05	0.00153	CcSEcCtD
Pemetrexed—Nervous system disorder—Epirubicin—bone cancer	1.78e-05	0.00153	CcSEcCtD
Pemetrexed—Thrombocytopenia—Epirubicin—bone cancer	1.77e-05	0.00153	CcSEcCtD
Pemetrexed—Hypertension—Doxorubicin—bone cancer	1.77e-05	0.00153	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Methotrexate—bone cancer	1.76e-05	0.00152	CcSEcCtD
Pemetrexed—Skin disorder—Epirubicin—bone cancer	1.76e-05	0.00152	CcSEcCtD
Pemetrexed—Chest pain—Doxorubicin—bone cancer	1.75e-05	0.00151	CcSEcCtD
Pemetrexed—Myalgia—Doxorubicin—bone cancer	1.75e-05	0.00151	CcSEcCtD
Pemetrexed—Arthralgia—Doxorubicin—bone cancer	1.75e-05	0.00151	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	1.74e-05	0.0015	CcSEcCtD
Pemetrexed—Anorexia—Epirubicin—bone cancer	1.73e-05	0.00149	CcSEcCtD
Pemetrexed—Dyspnoea—Methotrexate—bone cancer	1.73e-05	0.00149	CcSEcCtD
Pemetrexed—Dyspepsia—Methotrexate—bone cancer	1.7e-05	0.00147	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—DHFR—bone cancer	1.7e-05	0.00124	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—CYP3A4—bone cancer	1.7e-05	0.00124	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—ENO2—bone cancer	1.68e-05	0.00123	CbGpPWpGaD
Pemetrexed—Decreased appetite—Methotrexate—bone cancer	1.68e-05	0.00145	CcSEcCtD
Pemetrexed—Oedema—Doxorubicin—bone cancer	1.68e-05	0.00144	CcSEcCtD
Pemetrexed—Anaphylactic shock—Doxorubicin—bone cancer	1.68e-05	0.00144	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Methotrexate—bone cancer	1.67e-05	0.00144	CcSEcCtD
Pemetrexed—Fatigue—Methotrexate—bone cancer	1.67e-05	0.00144	CcSEcCtD
Pemetrexed—Infection—Doxorubicin—bone cancer	1.67e-05	0.00143	CcSEcCtD
Pemetrexed—Pain—Methotrexate—bone cancer	1.66e-05	0.00143	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Epirubicin—bone cancer	1.65e-05	0.00142	CcSEcCtD
Pemetrexed—Shock—Doxorubicin—bone cancer	1.65e-05	0.00142	CcSEcCtD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—TP53—bone cancer	1.65e-05	0.0012	CbGpPWpGaD
Pemetrexed—Nervous system disorder—Doxorubicin—bone cancer	1.64e-05	0.00142	CcSEcCtD
Pemetrexed—Thrombocytopenia—Doxorubicin—bone cancer	1.64e-05	0.00141	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—CHEK2—bone cancer	1.63e-05	0.00119	CbGpPWpGaD
Pemetrexed—Skin disorder—Doxorubicin—bone cancer	1.63e-05	0.0014	CcSEcCtD
Pemetrexed—Dyspnoea—Epirubicin—bone cancer	1.61e-05	0.00139	CcSEcCtD
Pemetrexed—Anorexia—Doxorubicin—bone cancer	1.6e-05	0.00138	CcSEcCtD
Pemetrexed—Dyspepsia—Epirubicin—bone cancer	1.59e-05	0.00137	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Methotrexate—bone cancer	1.58e-05	0.00136	CcSEcCtD
Pemetrexed—Decreased appetite—Epirubicin—bone cancer	1.57e-05	0.00136	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Epirubicin—bone cancer	1.56e-05	0.00135	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—DHFR—bone cancer	1.56e-05	0.00114	CbGpPWpGaD
Pemetrexed—Fatigue—Epirubicin—bone cancer	1.56e-05	0.00134	CcSEcCtD
Pemetrexed—Pain—Epirubicin—bone cancer	1.55e-05	0.00133	CcSEcCtD
Pemetrexed—Constipation—Epirubicin—bone cancer	1.55e-05	0.00133	CcSEcCtD
Pemetrexed—Urticaria—Methotrexate—bone cancer	1.54e-05	0.00132	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	1.53e-05	0.00112	CbGpPWpGaD
Pemetrexed—Body temperature increased—Methotrexate—bone cancer	1.53e-05	0.00132	CcSEcCtD
Pemetrexed—Abdominal pain—Methotrexate—bone cancer	1.53e-05	0.00132	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Doxorubicin—bone cancer	1.53e-05	0.00131	CcSEcCtD
Pemetrexed—Dyspnoea—Doxorubicin—bone cancer	1.49e-05	0.00129	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Epirubicin—bone cancer	1.48e-05	0.00128	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	1.48e-05	0.00108	CbGpPWpGaD
Pemetrexed—Dyspepsia—Doxorubicin—bone cancer	1.48e-05	0.00127	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—GNA11—bone cancer	1.46e-05	0.00107	CbGpPWpGaD
Pemetrexed—Decreased appetite—Doxorubicin—bone cancer	1.46e-05	0.00125	CcSEcCtD
Pemetrexed—ATIC—Metabolism—GSTP1—bone cancer	1.45e-05	0.00106	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Doxorubicin—bone cancer	1.45e-05	0.00125	CcSEcCtD
Pemetrexed—Fatigue—Doxorubicin—bone cancer	1.44e-05	0.00124	CcSEcCtD
Pemetrexed—Urticaria—Epirubicin—bone cancer	1.44e-05	0.00124	CcSEcCtD
Pemetrexed—Pain—Doxorubicin—bone cancer	1.43e-05	0.00123	CcSEcCtD
Pemetrexed—Constipation—Doxorubicin—bone cancer	1.43e-05	0.00123	CcSEcCtD
Pemetrexed—Abdominal pain—Epirubicin—bone cancer	1.43e-05	0.00123	CcSEcCtD
Pemetrexed—Body temperature increased—Epirubicin—bone cancer	1.43e-05	0.00123	CcSEcCtD
Pemetrexed—Hypersensitivity—Methotrexate—bone cancer	1.43e-05	0.00123	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—CHEK2—bone cancer	1.42e-05	0.00104	CbGpPWpGaD
Pemetrexed—Asthenia—Methotrexate—bone cancer	1.39e-05	0.0012	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—BRCA2—bone cancer	1.38e-05	0.00101	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Doxorubicin—bone cancer	1.37e-05	0.00118	CcSEcCtD
Pemetrexed—Pruritus—Methotrexate—bone cancer	1.37e-05	0.00118	CcSEcCtD
Pemetrexed—SLC46A1—Disease—TGFBR2—bone cancer	1.35e-05	0.000988	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Epirubicin—bone cancer	1.33e-05	0.00115	CcSEcCtD
Pemetrexed—Urticaria—Doxorubicin—bone cancer	1.33e-05	0.00115	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.33e-05	0.000972	CbGpPWpGaD
Pemetrexed—Abdominal pain—Doxorubicin—bone cancer	1.32e-05	0.00114	CcSEcCtD
Pemetrexed—Body temperature increased—Doxorubicin—bone cancer	1.32e-05	0.00114	CcSEcCtD
Pemetrexed—Diarrhoea—Methotrexate—bone cancer	1.32e-05	0.00114	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—CYP3A4—bone cancer	1.32e-05	0.000967	CbGpPWpGaD
Pemetrexed—Asthenia—Epirubicin—bone cancer	1.3e-05	0.00112	CcSEcCtD
Pemetrexed—Pruritus—Epirubicin—bone cancer	1.28e-05	0.0011	CcSEcCtD
Pemetrexed—Dizziness—Methotrexate—bone cancer	1.28e-05	0.0011	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—JUN—bone cancer	1.28e-05	0.000933	CbGpPWpGaD
Pemetrexed—Diarrhoea—Epirubicin—bone cancer	1.24e-05	0.00107	CcSEcCtD
Pemetrexed—Hypersensitivity—Doxorubicin—bone cancer	1.23e-05	0.00106	CcSEcCtD
Pemetrexed—Vomiting—Methotrexate—bone cancer	1.23e-05	0.00106	CcSEcCtD
Pemetrexed—Rash—Methotrexate—bone cancer	1.22e-05	0.00105	CcSEcCtD
Pemetrexed—Dermatitis—Methotrexate—bone cancer	1.22e-05	0.00105	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—BRCA2—bone cancer	1.21e-05	0.000881	CbGpPWpGaD
Pemetrexed—Asthenia—Doxorubicin—bone cancer	1.2e-05	0.00104	CcSEcCtD
Pemetrexed—Dizziness—Epirubicin—bone cancer	1.2e-05	0.00103	CcSEcCtD
Pemetrexed—Pruritus—Doxorubicin—bone cancer	1.19e-05	0.00102	CcSEcCtD
Pemetrexed—Vomiting—Epirubicin—bone cancer	1.15e-05	0.000992	CcSEcCtD
Pemetrexed—Nausea—Methotrexate—bone cancer	1.15e-05	0.00099	CcSEcCtD
Pemetrexed—Diarrhoea—Doxorubicin—bone cancer	1.15e-05	0.000988	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDK4—bone cancer	1.15e-05	0.000837	CbGpPWpGaD
Pemetrexed—Rash—Epirubicin—bone cancer	1.14e-05	0.000984	CcSEcCtD
Pemetrexed—Dermatitis—Epirubicin—bone cancer	1.14e-05	0.000983	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—GSTP1—bone cancer	1.13e-05	0.000827	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ENO2—bone cancer	1.12e-05	0.000821	CbGpPWpGaD
Pemetrexed—Dizziness—Doxorubicin—bone cancer	1.11e-05	0.000954	CcSEcCtD
Pemetrexed—GART—Metabolism—PTGS2—bone cancer	1.09e-05	0.000794	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ENO2—bone cancer	1.08e-05	0.000788	CbGpPWpGaD
Pemetrexed—Nausea—Epirubicin—bone cancer	1.08e-05	0.000927	CcSEcCtD
Pemetrexed—Vomiting—Doxorubicin—bone cancer	1.07e-05	0.000918	CcSEcCtD
Pemetrexed—Rash—Doxorubicin—bone cancer	1.06e-05	0.00091	CcSEcCtD
Pemetrexed—Dermatitis—Doxorubicin—bone cancer	1.06e-05	0.000909	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.05e-05	0.000764	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—DHFR—bone cancer	1.04e-05	0.000762	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDK4—bone cancer	1.02e-05	0.000748	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDK4—bone cancer	1e-05	0.00073	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—RB1—bone cancer	9.96e-06	0.000728	CbGpPWpGaD
Pemetrexed—Nausea—Doxorubicin—bone cancer	9.96e-06	0.000857	CcSEcCtD
Pemetrexed—DCK—Metabolism—GNA11—bone cancer	9.74e-06	0.000712	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—KIT—bone cancer	9.23e-06	0.000674	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ENO2—bone cancer	9.03e-06	0.00066	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDK4—bone cancer	8.94e-06	0.000653	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—RB1—bone cancer	8.91e-06	0.000651	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP3A4—bone cancer	8.83e-06	0.000645	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	8.79e-06	0.000642	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—RB1—bone cancer	8.69e-06	0.000635	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—BRAF—bone cancer	8.67e-06	0.000634	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—TP53—bone cancer	8.43e-06	0.000616	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ENO2—bone cancer	7.88e-06	0.000576	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GNA11—bone cancer	7.83e-06	0.000572	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—RB1—bone cancer	7.77e-06	0.000568	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MDM2—bone cancer	7.6e-06	0.000555	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTP1—bone cancer	7.56e-06	0.000552	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTGS2—bone cancer	7.53e-06	0.00055	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—DHFR—bone cancer	7.31e-06	0.000534	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MDM2—bone cancer	7.27e-06	0.000531	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TGFBR2—bone cancer	7.25e-06	0.00053	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP3A4—bone cancer	7.1e-06	0.000519	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTGS2—bone cancer	7.01e-06	0.000512	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GNA11—bone cancer	6.83e-06	0.000499	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MDM2—bone cancer	6.63e-06	0.000484	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP3A4—bone cancer	6.2e-06	0.000453	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTP1—bone cancer	6.07e-06	0.000444	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTGS2—bone cancer	5.87e-06	0.000429	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTP1—bone cancer	5.3e-06	0.000387	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EGFR—bone cancer	4.97e-06	0.000363	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KIT—bone cancer	4.95e-06	0.000361	CbGpPWpGaD
Pemetrexed—DHFR—Disease—BRAF—bone cancer	4.65e-06	0.00034	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TP53—bone cancer	4.36e-06	0.000318	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTGS2—bone cancer	3.91e-06	0.000286	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MDM2—bone cancer	3.9e-06	0.000285	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TP53—bone cancer	3.8e-06	0.000278	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTGS2—bone cancer	3.76e-06	0.000274	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTGS2—bone cancer	3.15e-06	0.00023	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTGS2—bone cancer	2.74e-06	0.000201	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EGFR—bone cancer	2.66e-06	0.000195	CbGpPWpGaD
